Table 2.
Comparison of LNM prevalence in different subgroups of patients with EPAC, non-EPAC differentiated EGC, and poorly differentiated EGC
| EPAC (N = 335) | Non-EPAC differentiated EGC (N = 1,077) | Poorly differentiated EGC (N = 1,101) | P—univariate analysis | |
| ≤2.0 cm | 23 (12.5%) | 31 (4.3%) | 117 (17.2%) | <0.001 |
| >2.0 cm, ≤3.0 cm | 18 (20.5%) | 22 (9.5%) | 64 (24.8%) | <0.001 |
| >3.0 cm | 21 (33.3%) | 17 (13.4%) | 51 (31.5%) | 0.001 |
| M | 3 (3.1%) | 8 (1.4%) | 60 (12.4%) | <0.001 |
| SM1 | 11 (14.3%) | 13 (5.8%) | 47 (24.2%) | <0.001 |
| SM2 | 48 (29.6%) | 49 (18.1%) | 125 (29.6%) | 0.002 |
| No ulceration | 51 (18.0%) | 47 (5.4%) | 162 (18.9%) | <0.001 |
| Ulceration | 11 (21.2%) | 23 (10.9%) | 70 (28.5%) | <0.001 |
| Absolute indication | 1 (2.0%) | 3 (0.8%) | — | 0.412 |
| Expanded indication | 9 (10.1%) | 12 (3.2%) | 28 (9.7%) | 0.001 |
| Relative indication | 52 (26.7%) | 55 (16.2%) | 204 (25.1%) | 0.002 |
EGC, early gastric carcinoma; EPAC, early gastric papillary adenocarcinoma; LNM, lymph node metastasis; M, confined to mucosa; SM1, <500 μm from the muscularis mucosae; SM2, confined to the submucosa and >500 μm from the muscularis mucosae.